This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.
|Original language||English (US)|
|Number of pages||4|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - 1993|
ASJC Scopus subject areas
- Cancer Research